logo
Scientists Discover a Viral Cause of One of The World's Most Common Cancers

Scientists Discover a Viral Cause of One of The World's Most Common Cancers

Yahoo07-08-2025
A common type of human papillomavirus (HPV) could be more dangerous than we thought. The virus, known as beta-HPV, was thought in rare cases to contribute to skin cancer by worsening UV damage, but a new study suggests it can actually hijack the body's cells to directly drive cancer growth.
These fresh conclusions came from a study of a 34-year-old woman who sought medical help for cutaneous squamous cell carcinoma (cSCC) on her forehead. Her tumors were repeatedly growing back, even after immunotherapy and surgeries.
Related:
A closer genetic analysis revealed something surprising: the beta-HPV had actually integrated itself into the DNA of the woman's tumor, where it was producing viral proteins that helped the cancer thrive.
Before now, beta-HPV had never been found to integrate into cellular DNA, let alone actively maintain a cancer.
"It suggests that there may be more people out there with aggressive forms of cSCC who have an underlying immune defect and could benefit from treatments targeting the immune system," says immunologist Andrea Lisco from the US National Institute of Allergy and Infectious Diseases (NIAID).
The woman who was the subject of this study had an inherited immune disorder, one which prevented her T cells from attacking HPV.
While tests revealed that the woman's immune system could still repair DNA damage from UV radiation – the typical cause of cSCC – the impairment of her T cells meant the beta-HPV could invade her skin cells and trigger the formation of cancer.
The immunocompromised woman was also being treated for other HPV-related illnesses, including warts on the skin and in the mouth.
Once the cause of her condition was discovered, the patient received a bone marrow stem cell transplant, to replace her dysfunctional T cells with healthy ones. This cleared up the aggressive skin cancer and her other HPV-caused issues, none of which returned during a three-year follow-up period.
"This discovery and successful outcome would not have been possible without the combined expertise of virologists, immunologists, oncologists and transplant specialists, all working under the same roof," says Lisco.
The study by no means minimizes the role of UV radiation as a cause of skin cancer, but shows that there are other factors at work too. In rare cases like this, normally benign viruses can have devastating effects in people with weakened immune systems.
That emphasizes the need for targeted, personalized cancer treatments that may well be more effective than conventional and generic approaches. It's likely that the woman involved in this study is far from the only one with this set of conditions.
Reason to be hopeful could come from progress against a related disease. Alpha-HPV is known as the cause of many cervical and throat cancers, and widespread vaccination against the virus has resulted in a drastic drop in deaths from those cancers.
While a single, universal cure for cancer remains elusive, we are continuing to see steadily improving survival and recovery rates across many cancer types, including cSCC – something this new research should also help with.
"This discovery could completely change how we think about the development, and consequently the treatment, of cSCC in people who have a health condition that compromises immune function," says Lisco.
The research has been published in The New England Journal of Medicine.
Related News
Alzheimer's May Start at The Brain's Borders, Scientists Discover
What Is Chikungunya? A Guide to The Virus Spreading in China
A Disease That Makes You Allergic to Meat And Dairy Is Spreading Around The World
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Anti-vaccine group that Robert F. Kennedy Jr. founded files lawsuit against him over vaccine safety task force
Anti-vaccine group that Robert F. Kennedy Jr. founded files lawsuit against him over vaccine safety task force

CNN

timean hour ago

  • CNN

Anti-vaccine group that Robert F. Kennedy Jr. founded files lawsuit against him over vaccine safety task force

Vaccines Children's health Federal agenciesFacebookTweetLink Follow A nonprofit anti-vaccine group founded by Robert F. Kennedy Jr. said it is funding a lawsuit against him, in his capacity as secretary of the US Department of Health and Human Services, for failing to establish a task force to promote the development of safer childhood vaccines. 'Our first priority will ALWAYS be children's health. Sec. Kennedy has FAILED 'to establish a task force dedicated to making childhood vaccines safer, as mandated by federal law,' so we WILL be holding him accountable,' Children's Health Defense said Tuesday in a post on X. The tactic is one familiar to both parties. When Kennedy was head of Children's Health Defense, he filed dozens of lawsuits against corporations and government agencies, usually over vaccines. 'It's difficult to know how much of this is performative,' Dr. Peter Hotez, who co-directs the Center for Vaccine Development at Texas Children's Hospital in Houston, said in an email. 'The steady stream of pseudoscience policies and propaganda pushed out of the Humphrey Building in Washington DC are both straight out of playbook from both RFK jr and CHD. As far as I can tell there is no real daylight between the two.' The National Childhood Vaccine Injury Act of 1986 directs the HHS secretary to establish a task force consisting of the director of the National Institutes of Health, the commissioner of the Food and Drug Administration and the director of the Centers for Disease Control and Prevention. The NIH director is designated as chair. According to an article posted Monday on Children's Health Defense's news site, in the years since the act was passed, no HHS secretary – including Kennedy – has ever reported to Congress on steps taken to make vaccines safer. 'This is part of the 1986 act itself,' Children's Health Defense CEO Mary Holland said in the article. 'That no secretary has done so since the passage of this law is a blow to the rule of law. I hope and trust that the current secretary will fulfill his obligation to Congress's mandate.' The task force was indeed created, but it was short-lived, issuing its final report in 1998. Since then, Kennedy has used the absence of the panel to mischaracterize the government's efforts to ensure the safety of vaccines. He's floated the idea of reviving the panel – or one like it – on vaccine safety for years. Children's Health Defense says attorney Ray Flores, its senior outside counsel, filed the lawsuit. Kennedy filed a similar suit in 2018 after a Freedom of Information Act request failed to produce any of the reports that are supposed to be filed under the Act, including the 1998 report. HHS has not responded to CNN's request for comment about the new lawsuit. Dorit Reiss, a professor of law at UC Law San Francisco, also said the lawsuit 'looks performative.' 'It may give Kennedy cover for convening this task force that he may already want to convene. It may well be collusion,' she said in an email. 'To me, this looks like a way to give political cover to something the Secretary may want to do anyway (and can do without anything). The government has answers to this lawsuit, but may not want to. 'Even if it does not include the people in the [National Childhood Vaccine Injury Act], there are multiple federal committees that routinely look at vaccine safety and how to make vaccines safer. It's something that gets a lot of attention,' Reiss wrote. Correction: A previous version of this story incorrectly described who filed the lawsuit against HHS Secretary Robert F. Kennedy Jr. The lawsuit was filed by attorney Ray Flores and Children's Health Defense says it's funding the lawsuit.

Kansas coach Bill Self undergoes heart procedure
Kansas coach Bill Self undergoes heart procedure

Yahoo

time2 hours ago

  • Yahoo

Kansas coach Bill Self undergoes heart procedure

Kansas men's basketball coach Bill Self was transported to Lawrence Memorial Hospital on Thursday after he 'experienced some concerning symptoms,' according to a statement from Kansas Athletics. Self had two stents inserted during a heart procedure that 'went very well,' and he is expected to make a full recovery. 'He is in good spirits and expects to be released from the hospital soon.' The university did not disclose any information regarding a timetable for Self's recovery or whether he will miss the upcoming basketball season. Self previously underwent a heart procedure and had two stents placed to treat blocked arteries in 2023. The veteran coach had experienced chest tightness and had concerns about his balance after watching shooting as his team was preparing for a Big 12 tournament quarterfinal game that year. He recovered and was present at NCAA Tournament practices, but did not fully return to coaching on the sideline for games until the following season. Who is Bill Self? Bill Self has spent the past 22 seasons as Kansas' head basketball coach, winning the national championship in 2008 and 2022. The Jayhawks have qualified for the NCAA Tournament 21 times during Self's tenure, only missing the 2020 season when the tournament was canceled due to the COVID-19 pandemic. He has compiled a 624-156 overall record during his time at Kansas. When does Kansas open the 2025-26 season? Kansas has exhibition games scheduled against Louisville (Oct. 24) and Fort Hays State (Oct. 28) before opening the season against Green Bay on Nov. 3 and North Carolina on Nov. 7. This article originally appeared on USA TODAY: Bill Self update: Kansas men's basketball coach has heart procedure

Precigen Stock (PGEN) Roars Over 60% Higher on FDA Green Light for Papzimeos Therapy
Precigen Stock (PGEN) Roars Over 60% Higher on FDA Green Light for Papzimeos Therapy

Business Insider

time2 hours ago

  • Business Insider

Precigen Stock (PGEN) Roars Over 60% Higher on FDA Green Light for Papzimeos Therapy

Shares in biopharmaceutical company Precigen (PGEN) rocketed higher today after the U.S. Food and Drug Administration gave the green light to a therapy to treat a rare respiratory disease. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The approval of the therapy, called Papzimeos, is the first treatment for the condition to receive the health regulator's nod. Fatal Tumors Papzimeos has been approved to treat recurrent respiratory papillomatosis (RRP) — a condition that causes growth of wart-like tumors in the respiratory tract due to human papillomavirus (HPV) infection. RRP can lead to severe voice disturbance, a compromised airway, and recurrent post-obstructive pneumonias. Precigen estimates that there are about 27,000 adult RRP patients in the U.S. RRP can be fatal as there is no cure and the current standard-of-care is repeated surgeries. However, despite being removed in these surgeries, the growth has a tendency to return. 'For more than a century, since RRP was first recognized as a distinct disease, patients have had to rely on repeated surgeries to manage this relentless condition. Today marks a historic turning point. With the landmark FDA approval all adult RRP patients are now eligible for access to the first and only approved therapy that targets the root cause of the disease,' said Helen Sabzevari, PhD, President and CEO of Precigen. Analyst Upgrade Simon Best, associate professor of Otolaryngology at Johns Hopkins Hospital, added: 'Everybody is anxiously awaiting a new treatment for this disease. The patients are and the surgeons are. There's nothing more frustrating than doing a surgery and then having the patient come back six months later.' The approval was based on an early-to-mid-stage study data that showed 51% of patients required no surgeries in the 12 months after the treatment. upgraded Precigen to Neutral from Underweight on the news. It cited the removal of Precigen's 'major regulatory overhang' and its revenue potential for the upgrade. It estimates that peak sales for the drug in the U.S. to be about $250 million. Precigen is certainly making strides when it comes to its financials – as can be seen below. Precigen recently reported a Q2 net loss of $26.6 million, a significant improvement from the $58.8 million loss in the same period last year. Total revenues for the quarter were $856,000, up from $717,000 in the previous year, driven by increased service revenues. Is PGEN a Good Stock to Buy Now? On TipRanks, PGEN has a Hold consensus based on 2 Buy, 1 Hold and 1 Sell ratings. Its highest price target is $6. PGEN stock's consensus price target is $4.50, implying a 143.24% upside.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store